Lifeline Biotechnologies Retains Legal Counsel to Resolve Trading Issue with Depository Trust Services
09 July 2010 - 11:00PM
Business Wire
Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) announced
today that it has retained legal counsel to resolve the trading
issue with Depository Trust Corporation (DTC) in order to
re-establish clearing services.
Jim Holmes, Lifeline’s CEO, said, “We have retained special
counsel to assist us in re-establishing Depository Trust’s services
to our Company. The law firm we have retained has been successful
in re-establishing DTC’s services to other public companies who,
the SEC alleges, were a part of the LEEB Brokerage Services’
questionable stock transactions, and is currently working with
DTC’s outside legal counsel to remove the ‘chill’ that was placed
on our stock in May.”
Holmes reaffirmed, “We have no association or knowledge of LEEB,
its counterparts, representatives or their activities concerning
the trading of Lifeline’s shares.”
DTC is the clearing agency for public stock transactions. The
broker-dealers clear trades through DTC. Currently public stock
trades transactions are cleared through the DTC electronic
system.
The Company remains focused, and its priority is the preparation
and submission of a First Warning System™ medical device 510(k)
application and commensurate commercialization.
Lifeline’s website (www.lbti.com) has been comprehensively
updated providing extensive information on the company, its history
and current affairs.
Safe Harbor: This release includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 27E of the Securities Act of 1934. Statements contained in
this release that are not historical facts may be deemed to be
forward-looking statements. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual
performance and results may differ materially from that projected
or suggested herein due to certain risks and uncertainties
including, without limitation, the ability to obtain financing,
successful development of the Company's product or market
acceptance of the product and regulatory and shareholder approval
for anticipated actions.
Lifeline Biotech (CE) (USOTC:LLBO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Lifeline Biotech (CE) (USOTC:LLBO)
Historical Stock Chart
From Dec 2023 to Dec 2024
Real-Time news about Lifeline Biotech Inc (CE) (OTCMarkets): 0 recent articles
More Lifeline Biotechnologies, Inc. News Articles